argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
argenx (Euronext & Nasdaq: ARGX) announced that CEO Tim Van Hauwermeiren will present at the 44th Annual J.P.
Rhea-AI Summary
argenx (Euronext & Nasdaq: ARGX) announced that CEO Tim Van Hauwermeiren will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.
A live webcast will be available on the company's Investors website at argenx.com/investors, and a replay will be accessible on the site for approximately 30 days after the presentation.
Details
News Market Reaction – ARGX
On Jan 6, the day this news came out, ARGX closed 0.36% above the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation date
- January 12, 2026
- Scheduled conference presentation
- Presentation time
- 8:15 a.m. PT
- Start time of CEO presentation
- Webcast replay period
- 30 days
- Replay availability on company website
Historical Context
-
Phase 3 UplighTED studies discontinued after futility recommendation.
-
Extraordinary meeting approved new remuneration policy with strong support.
-
Reported strong Q3 2025 results and reaffirmed R&D and SG&A guidance.
-
New VYVGART data showed efficacy and favorable safety in myasthenia gravis.
-
Announcement of timing and access details for Q3 2025 results call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
January 6, 2026
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.
A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.
For further information, please contact:
Media:
Ben Petok
bpetok@argenx.com
Investors:
Alexandra Roy
aroy@argenx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.